Evidence Analysis

It is a challenge for health plans and clinicians to distill and analyze volumes of clinical evidence to determine likely clinical, financial, and risk impacts. This is what we do.

Accessed through the Hayes Knowledge Center, the Evidence Analysis Solution addresses the following fundamental questions to help our clients determine coverage positions:

  • Does the technology improve health outcomes?
  • Are there other benefits associated with the technology?
  • What harms might be associated with the technology?
  • Have patient selection criteria been established for the technology?
  • For which patients might the technology provide a benefit?

Minimally Invasive Sacroiliac Joint Fusion Using Cylindrical Threaded Implants

Focus of the Report: The use of minimally invasive sacroiliac joint (SIJ) fusion with cylindrical threaded implants (CTIs) for the treatment of adults with SIJ dysfunction who have not experienced adequate relief from nonsurgical management (NSM). Evaluation of minimally invasive SIJ fusion using triangular titanium implants (i.e., iFuse Impl…

Amniotic Allografts for Tendon and Ligament Injuries

Focus of the Report: This report focuses on amniotic allograft (AA) for treatment or prevention of tendon and ligament injuries.

Technology Description: AA is prepared from sheets of amniotic membrane obtained shortly after caesarean delivery. For some products, amniotic membrane is de…

Erenumab (Aimovig) for Prevention of Episodic or Chronic Migraine

Focus of the Report: This Health Technology Assessment focuses on the efficacy and safety of a monoclonal antibody, erenumab (Aimovig), for prevention of episodic or chronic migraine.

Technology Description: Erenumab is a human calcitonin gene–related peptide (CGRP) receptor monoclonal antibody that is produced using recombinant DNA technology in cell …

Onasemnogene Abeparvovec-xioi (Zolgensma) for Spinal Muscular Atrophy

Focus of the Report: This report evaluates the efficacy and safety of the gene replacement therapy onasemnogene abeparvovec-xioi (Zolgensma or AVXS-101) for treatment of patients with spinal muscular atrophy (SMA) type 1.

Technology Description: Onasemnogene abeparvovec is a single-dos…

Skin Substitutes for Venous Leg Ulcers in Adults

Focus of the Report: This report compares the effectiveness and safety of skin substitutes (cellular and acellular) as an addition to standard wound care (SWC) with SWC alone and compared with the adjunct use of alternative skin substitute products to treat chronic or nonhealing venous leg ulcers in adults.